Literature DB >> 8532986

On the use of a pilot sample for sample size determination.

R H Browne1.   

Abstract

To compute the sample size needed to achieve the planned power for a t-test, one needs an estimate of the population standard deviation sigma. If one uses the sample standard deviation from a small pilot study as an estimate of sigma, it is quite likely that the actual power for the planned study will be less than the planned power. Monte Carlo simulations indicate that using a 100(1-gamma) per cent upper one-sided confidence limit on sigma will provide a sample size sufficient to achieve the planned power in at least 100(1-gamma) per cent of such trials.

Mesh:

Year:  1995        PMID: 8532986     DOI: 10.1002/sim.4780141709

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  226 in total

1.  BIAS IN LINEAR MODEL POWER AND SAMPLE SIZE DUE TO ESTIMATING VARIANCE.

Authors:  Keith E Muller; Virginia B Pasour
Journal:  Commun Stat Theory Methods       Date:  1997       Impact factor: 0.893

2.  Power calculation for overall hypothesis testing with high-dimensional commensurate outcomes.

Authors:  Yueh-Yun Chi; Matthew J Gribbin; Jacqueline L Johnson; Keith E Muller
Journal:  Stat Med       Date:  2013-09-30       Impact factor: 2.373

3.  Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial.

Authors:  Joseph Butchart; Laura Brook; Vivienne Hopkins; Jessica Teeling; Ursula Püntener; David Culliford; Richard Sharples; Saif Sharif; Brady McFarlane; Rachel Raybould; Rhodri Thomas; Peter Passmore; V Hugh Perry; Clive Holmes
Journal:  Neurology       Date:  2015-05-01       Impact factor: 9.910

4.  Vigorous intensity aerobic interval exercise in bladder cancer patients prior to radical cystectomy: a feasibility randomised controlled trial.

Authors:  Srijit Banerjee; Kate Manley; Barnabas Shaw; Liane Lewis; Gabriel Cucato; Robert Mills; Mark Rochester; Allan Clark; John M Saxton
Journal:  Support Care Cancer       Date:  2017-11-27       Impact factor: 3.603

5.  Improvement in resiliency factors among adolescents with neurofibromatosis who participate in a virtual mind-body group program.

Authors:  Ethan G Lester; Eric A Macklin; Scott Plotkin; Ana-Maria Vranceanu
Journal:  J Neurooncol       Date:  2020-02-20       Impact factor: 4.130

6.  The impact of a mind-body program on multiple dimensions of resiliency among geographically diverse patients with neurofibromatosis.

Authors:  Emily L Zale; Catherine Pierre-Louis; Eric A Macklin; Eric Riklin; Ana-Maria Vranceanu
Journal:  J Neurooncol       Date:  2017-12-23       Impact factor: 4.130

7.  Improving AIDS Care After Trauma (ImpACT): Pilot Outcomes of a Coping intervention Among HIV-Infected Women with Sexual Trauma in South Africa.

Authors:  Kathleen J Sikkema; Marta I Mulawa; Corne Robertson; Melissa H Watt; Nonceba Ciya; Dan J Stein; Emily M Cherenack; Karmel W Choi; Matapelo Kombora; John A Joska
Journal:  AIDS Behav       Date:  2018-03

8.  Testing a brief self-directed behavioral weight control program.

Authors:  Jennifer A Linde; Robert W Jeffery
Journal:  Behav Med       Date:  2011-04       Impact factor: 3.104

9.  The effectiveness of solution-focused brief therapy for psychological distress among Chinese parents of children with a cancer diagnosis: a pilot randomized controlled trial.

Authors:  Anao Zhang; QingYing Ji; Jennifer Currin-McCulloch; Phyllis Solomon; YuTing Chen; Yaxi Li; Barbara Jones; Cynthia Franklin; Jack Nowicki
Journal:  Support Care Cancer       Date:  2018-03-15       Impact factor: 3.603

10.  A cluster randomized pilot trial of a tailored worksite smoking cessation intervention targeting Hispanic/Latino construction workers: Intervention development and research design.

Authors:  Taghrid Asfar; Alberto J Caban-Martinez; Laura A McClure; Estefania C Ruano-Herreria; Danielle Sierra; G Gilford Clark; Daniel Samano; Noella A Dietz; Kenneth D Ward; Kristopher L Arheart; David J Lee
Journal:  Contemp Clin Trials       Date:  2018-02-14       Impact factor: 2.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.